Betta Pharmaceuticals Subsidiary's Anti-Cancer Capsules Gets Australia Clinical Trial Nod
MT Newswires Live
Sep 29
Betta Pharmaceuticals' (SHE:300558) BPI-572270 capsules manufactured by subsidiary Hangzhou Jingyao Biotechnology will begin phase 1/2 clinical trials in Australia, according to a Monday after-hours filing with the Shenzhen bourse.
Betta Pharmaceuticals' shares rose 3% during the midday break on Tuesday.
The drug is indicated for advanced solid tumors with specific RAS mutations, such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer, among others, the drug company said in its release.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.